TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
29. März 2016 02:02 ET
|
AstraZeneca PLC
TAGRISSO™ (OSIMERTINIB) approved in japan for PATIENTS WITH EGFR T790M mutation
-positive metastatic non-small cell lung cancer
Full approval is based on two Phase II trials, AURA extension and...
Director/PDMR Shareholding
24. März 2016 11:00 ET
|
AstraZeneca PLC
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 24 March 2016, the individuals listed below, who are all persons discharging
managerial responsibilities,...
AZ reports results from Brilinta stroke trial
23. März 2016 03:00 ET
|
AstraZeneca PLC
ASTRAZENECA REPORTS TOP-LINE RESULTS FROM THE BRILINTA SOCRATES TRIAL IN STROKE
Missed primary efficacy endpoint; fewer events observed in the Brilinta arm but
trend did not reach statistical...
Notice of AGM
18. März 2016 06:30 ET
|
AstraZeneca PLC
NOTICE OF ANNUAL GENERAL MEETING
AstraZeneca PLC (the Company) announced today the publication of its Notice of
Annual General Meeting 2016 and Shareholders' Circular, together with a covering
letter...
Filing of Form 20-F with SEC
08. März 2016 13:34 ET
|
AstraZeneca PLC
FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE
COMMISSION
AstraZeneca PLC (the Company) announced today that it filed its Annual Report on
Form 20-F with the US Securities...
Annual Financial Report
08. März 2016 07:04 ET
|
AstraZeneca PLC
ANNUAL FINANCIAL REPORT
AstraZeneca PLC (the Company) announced today the publication of its Annual
Report and Form 20-F Information 2015 (Annual Report).
A copy of the Annual Report will be...
AZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
29. Februar 2016 09:37 ET
|
AstraZeneca PLC
ASTRAZENECA REPORTS TOP-LINE RESULT OF TREMELIMUMAB MONOTHERAPY TRIAL IN
MESOTHELIOMA
Trial did not meet primary endpoint of improving overall survival in challenging
to treat mesothelioma patients...
AZ enters licensing agreement with CMS for Plendil
29. Februar 2016 02:59 ET
|
AstraZeneca PLC
ASTRAZENECA ENTERS LICENSING AGREEMENT WITH CHINA MEDICAL SYSTEM HOLDINGS FOR
HYPERTENSION MEDICINE
Agreement for Plendil in China reinforces AstraZeneca's focus on...
Director/PDMR Shareholding
26. Februar 2016 07:00 ET
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 25 February 2016, the interest of Mr Pascal Soriot, a person discharging
managerial responsibilities, in...
ACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
25. Februar 2016 04:07 ET
|
AstraZeneca PLC
Acalabrutinib RecommendEd for Orphan Drug Designation IN EUROPE for THREE
indications
AstraZeneca and Acerta Pharma BV, a company in which AstraZeneca has a majority
equity investment, today...